What is AXNX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AXNX?

P/E (TTM) is n/a and 52-week range is $47.61 to $71.97 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AXNX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AXNX?

The company profile lists revenue (TTM) near $432M, net income (TTM) near $-566M, EPS (TTM) near $-0.11 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Axonics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Irvine, California, US, 51.1M shares outstanding, ISIN US05465P1012 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Axonics Inc

$AXNX

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.71

-99.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.

Employees

797

Website

www.axonics.com/

IPO

2018-10-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)